Insider Selling: Veracyte Insider Unloads 3,000 Shares of Stock (VCYT)
Veracyte (NASDAQ:VCYT) Insider Christopher M. Hall sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, July 10th. The stock was sold at an average price of $14.92, for a total value of $44,760.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Veracyte (NASDAQ:VCYT) traded down 2.41% during mid-day trading on Friday, hitting $14.56. 29,659 shares of the company’s stock traded hands. Veracyte has a 52 week low of $10.88 and a 52 week high of $19.00. The stock has a 50-day moving average of $15.51 and a 200-day moving average of $15.1. The company’s market cap is $308.3 million.
Veracyte (NASDAQ:VCYT) last released its earnings data on Thursday, May 8th. The company reported ($0.32) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.31) by $0.01. The company had revenue of $7.50 million for the quarter, compared to the consensus estimate of $7.19 million. During the same quarter in the prior year, the company posted ($9.04) earnings per share. The company’s quarterly revenue was up 70.5% on a year-over-year basis. Analysts expect that Veracyte will post $-1.29 EPS for the current fiscal year.
A number of analysts have recently weighed in on VCYT shares. Analysts at Janney Montgomery Scott initiated coverage on shares of Veracyte in a research note on Thursday, June 26th. They set a “buy” rating and a $25.00 price target on the stock. Analysts at Piper Jaffray initiated coverage on shares of Veracyte in a research note on Thursday, June 19th. They set an “overweight” rating and a $21.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $21.40.
Veracyte, Inc is a diagnostics company focused on molecular cytology. The Company focuses on diseases that often require invasive procedures for an accurate diagnosis.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.